miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru

26 Apr 2019 - Yahoo News
BOULDER, Colo., April 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced incremental new data from its Phase 1 clinical trial evaluating the safety, tolerability ...
usx:mgen

---

miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th

25 Apr 2019 - Yahoo News
BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 8th, at 4:30 p.m. ET to discuss its financial results for ...
usx:mgen

---

Miragen Therapeutics Inc (MGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

15 Mar 2019 - Yahoo News
Miragen Therapeutics Inc is a clinical-stage biopharmaceutical company which engaged in discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapeutics. Miragen Therapeutics Inc had annual average EBITDA growth of 4.00% over the past five years. Warning! GuruFocus has detected 3 ...
usx:mgen

---

Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates

14 Mar 2019 - Nasdaq
Signal Genetics Inc MGEN came out with a quarterly loss of 0 33 per share versus the Zacks Consensus Estimate of a loss of 0 31 This compares to loss of 0 29 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise
usx:mgen

---

Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Misses Revenue Estimates

13 Mar 2019 - Yahoo News
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -6.45% and -69.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
usx:mgen

---

miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook

13 Mar 2019 - Yahoo News
BOULDER, Colo., March 13, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial and operating results for the fourth quarter and full-year ended ...
usx:mgen

---

miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference

6 Mar 2019 - Yahoo News
BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a ...
usx:mgen

---

miRagen Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results and Host a Conference Call on March 13th

20 Feb 2019 - Yahoo News
BOULDER, Colo., Feb. 20, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, March 13, at 4:30 p.m. ET to discuss its financial results for ...
usx:mgen

---

Colorado biotech firms are developing drugs to fight cancer, help children and cut down on excessive sweating

24 Jan 2019 - Yahoo News
When it comes to top biotech clusters in the country, Colorado is in the conversation, but has a way to go to be mentioned in the same breath as California and Massachusetts, where a majority of investor money goes into drug development. “I’d say it’s really on fire right now,” said Frank Segrave, CEO ...
usx:mgen

---

miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

10 Jan 2019 - Yahoo News
50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response lasting for greater than four months (ORR4)Evidence of disease stabilization.
usx:mgen

---